Distribution agreement with Australian Allografts

Tissue Regenix

25/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230525:nRSY5815Aa&default-theme=true

RNS Number : 5815A  Tissue Regenix Group PLC  25 May 2023

Tissue Regenix Group plc

('Tissue Regenix', the 'Company' or the 'Group')

 

Multi-year distribution agreement with Australian Allografts

 

Tissue Regenix (AIM: TRX), the regenerative medical device company, announces
that it has signed an exclusive distribution agreement with Australian
Allografts for the distribution of the Tissue Regenix OrthoPure(®) XT
product in Australia and New Zealand. This is subject to regulatory approval
from the Therapeutic Goods Administration ('TGA').

 

As part of the agreement, Australian Allografts and Tissue Regenix are
mutually committed to achieving the TGA regulatory approval process to enable
the import and distribution of the products. The initial distribution
agreement is for three years and requires Australian Allografts to purchase a
minimum unit volume each year after achieving the TGA approval.

 

The OrthoPure® XT decellularised xenograft ligament utilises Tissue Regenix's
patented dCELL® technology and is the only available, non-human biologic
graft for certain anterior cruciate ligament ('ACL') reconstruction procedures
on the market. OrthoPure® XT can also be used in the reconstruction of other
knee ligaments, including multi-ligament and primary procedures when an
autograft is not an option.

 

Kirsten Lund, EMEA Business Director for Tissue Regenix, said: "This
distribution agreement will allow physicians and patients better access to our
innovative products through the Australian Allografts network and is another
major step towards Tissue Regenix becoming a global player in the regenerative
medicine market. We look forward to working with Australian Allografts."

 

Andrew Lambing, Managing Director for Australian Allografts, commented: "We
are excited to partner with Tissue Regenix, bringing together two
organisations with a clear focus for best patient outcome and delivering the
latest technologies in tissue development and processing for Australia and New
Zealand."

 

For more information:

 

 Tissue Regenix Group plc                                               www.tissueregenix.com (http://www.tissueregenix.com)
 Daniel Lee, Chief Executive Officer                                    via Walbrook PR

 finnCap Ltd (Nominated Adviser and Broker)
 Emily Watts/Geoff Nash/George Dollemore - Corporate Finance
 Nigel Birks/Harriet Ward - ECM

 Walbrook PR (Financial PR and IR)  Tel: +44 (0)20 7933 8780
 Alice Woodings/Lianne Applegarth   TissueRegenix@walbrookpr.com (mailto:TissueRegenix@walbrookpr.com)

 

About Tissue Regenix (www.tissueregenix.com (http://www.tissueregenix.com) )

Tissue Regenix is a leading medical device company in regenerative medicine.
The Company's patented decellularisation technology ('dCELL®') removes DNA
and other cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold not rejected by the patient's body that can be used
to repair diseased or damaged body structures. Current applications address
many crucial clinical needs in sports medicine, foot and ankle and wound care.

 

In August 2017, Tissue Regenix acquired CellRight Technologies®. This
biotech company specialises in regenerative medicine and is dedicated to
developing high-quality, innovative tissue scaffolds to enhance healing
opportunities in defects created by trauma and disease. CellRight's human
tissue products may be used in spine, trauma, general orthopaedic, dental and
ophthalmological surgical procedures.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGREAFSLADNDEAA